History Mission Strategic plan Role The FAMHP also ensures that … Our core business Our organisation Organisation chart Our vision and values Vision and ambition Values Commitments by federal administrations Our stakeholders Partners FAMHP customer charter Partners receiving financial support from the FAMHP The FAMHP and European projects Disclaimer Transparency Social media Conditions for reuse (Creative Commons-0 licence)
12/05/2025 PRAC May 2025 - New risk mitigation measures for finasteride and dutasteride and start of a review of the Ixchiq vaccine
19/05/2025 The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine SPVN20 for the treatment of rod-cone dystrophy. The public consultation will take place from 19 May to 18 Jun